ArticleCancers2025
Automated Clinical Dosimetry Planning of Dense Lattice Radiation Therapy.
Article in Cancers, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- The future is not always uniform: rethinking radiotherapy through spatial fractionation.Nature reviews. Clinical oncology · 2026Review
- Feasibility, safety, and clinical outcomes analysis of dense-lattice radiation therapy in palliative care for cancer patients´.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPatients bearing large-volume, bulky primary or relapsed tumors, are usually referred to palliative low-dose radiotherapy with very poor results. Lattice Radiation Therapy (LRT) is able to produce a high number of high-dose foci or vortexes (multiple SBRT treatments), separated by low-dose zones (valleys). Treatment planning on vortex placing, valley definition, and dose administered depends on individual decisions of the treating team. The aim of our study is to assess for the first time the possibility of a dense fractionated LRT within the target volume.
methodsA total of 22 treatments in 20 patients were performed in the frame of a prospective observational study of fractionated LRT ongoing in our institution. According to our aim of achieving dense LRT, no GTV contraction was considered to create the LRTV (GTV is equal to LRTV). The vortexes were segmented as 1 cm diameter at a 1.5 cm vortex-to-vortex distance. Dose prescription to the vortexes per fraction was 12 Gy.
resultsThe vortex/LRTV ratio was 7.38 ± 2.13% (3.4-10.40%, median 7.60%). Mean dose to the vortex volume was 11.90 ± 0.09 Gy (11.70-12.10 Gy, median 11.90 Gy). Mean dose administered to the valley volume was 8.29 ± 0.70 (7.05-9.51 Gy, median 8.29 Gy). Valley/vortex (peak) dose ratio (VPDR) was 69.40 ± 6.02% (59.00-79.80%, median 69.70%). The mean peripheral tumor dose was 5.11 ± 0.8710 Gy (3.16-6.78 Gy, median 5.18 Gy).
conclusionsOur dense LRT schedule fulfilled most of the recommended guidelines for LRT, increasing the high dose points without risking the dose to the surrounding tissues. Further analysis of feasibility and safety are needed to secure the clinical relevance of our proposed protocol.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.